Kun He

U.S. Food and Drug Administration Approval: Vismodegib for Recurrent, Locally Advanced, or Metastatic Basal Cell Carcinoma

Michael D. Axelson, Ke Liu, Xiaoping Jiang et al. · Clinical Cancer Research · 2013 · 187 citations · Full text

Medicine, Oncology, Pharmacology +15

FDA Review Summary: Mozobil in Combination with Granulocyte Colony-Stimulating Factor to Mobilize Hematopoietic Stem Cells to the Peripheral Blood for Collection and Subsequent Autologous Transplantation

Michael H. Brave, Ann T. Farrell, Sue Ching Lin et al. · Oncology · 2010 · 143 citations

Medicine, Hematology, Pharmacology +17

U.S. Food and Drug Administration Approval Summary: Erlotinib for the First-Line Treatment of Metastatic Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 19 Deletions or Exon 21 (L858R) Substitution Mutations

Sean Khozin, Gideon M. Blumenthal, Xiaoping Jiang et al. · The Oncologist · 2014 · 142 citations · Full text

Medicine, Oncology, Pharmacology +14

FDA Approval Summary: Sonidegib for Locally Advanced Basal Cell Carcinoma

Denise Casey, Suzanne Demko, Stacy S. Shord et al. · Clinical Cancer Research · 2017 · 129 citations · Full text

Medicine, Oncology, Pharmacology +7

Decreased expression of LncRNA SLC25A25-AS1 promotes proliferation, chemoresistance, and EMT in colorectal cancer cells

Yuan Li, Shengkai Huang, Yan Li et al. · Tumor Biology · 2016 · 70 citations

Medicine, Molecular Biology, Oncology +17